CA-NEXON-AMERICA
16.12.2021 23:05:06 CET | Business Wire | Press release
MapleStory M , Nexon’s popular free-to-play mobile MMORPG, has officially launched its latest update, bringing the long-awaited Pathfinder class to the game alongside a flurry of winter season events and activities for Maplers to tackle. The Pathfinder update has also increased the max level to 250, and brings new daily and weekly missions, achievements, and a new mini-dungeon to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006140/en/
As of today, the sharpshooting Explorer who wields an ancient bow, Pathfinder, is available as a new playable class. Maplers who pre-registered their Pathfinder were eligible for items such as Auto Battle Charge Tickets and EXP tickets, while all players can take part in Mega Burning and On-Time/Growth Support events to help level-up a new Pathfinder quickly. As a bonus after today’s maintenance, both MapleStory M and MapleStory will be running the Pathfinder Link Event through January 19, 2022, whereby, after reaching level, 70, 120, and 140 on MapleStory M with the Pathfinder, Maplers can garner rewards in both games, including a Pathfinder outfit gift box, Ancient Relic, and more.
The Black Mage's fourth commander, Arkarium, formerly a servant under Rhinne, Maple World's Transcendent of Time, makes his debut in MapleStory M . Maplers will be able to craft all-new boss accessory Dominator Pendant using the materials acquired when defeating Arkarium.
A new map in the Arcane River has also been added, the Dreaming City Lachelein , bringing with it new quests, monsters, area items to discover, and a new Arcane force field. Mini-dungeons have also received a quality of life improvement with this update so that Maplers can auto-play multiple times by using tickets and mesos.
In addition to the events celebrating the arrival of Pathfinder, players can look forward to numerous winter seasonal events occurring throughout December and into the new year:
- I&B Burning Challenge Mission Event - From December 15, 2021 through January 19, 2022, this event returns, granting not only Ice Agent or Burning Agent player titles, but also granting daily missions for players to conquer.
- Holiday Mr. Kim’s Gift - From December 22 through December 30, 2021, tapping on Mr. Kim will reward players with special items.
-
Winter Happyville
Events
- (Various scheduled times - refer to in-game event banner or see MapleStoryM
patch notes for exact times and dates for each event.) Winter Happy Village will play host to multiple winter events throughout December and January :
- Coin Drop Event
- A Well-Behaved Child Needs A Gift!
- A Crying Child Also Needs A Gift!
- Buff Tree Event
- Great Rudolph Escape
- 2022 Countdown Event - From December 23, 2021 through January 6, 2022, players can enter the event map every day and receive EXP for ten minutes. After spending ten minutes on the map, these players will receive a countdown reward and, on January 1, Maplers can earn a special New Year reward!
- Snowflake Snowpark - From January 6 through January 18, 2022, Maplers can earn AB tickets, EXP tickets, and Gold Leaf by clearing different missions and receiving stamps.
- 2022 New Year Wheel - From January 13 through January 27, 2022, players can receive a maximum of 5 wheel tickets per day by hunting. Rewards for participating in the event include AB tickets, Luckyday scroll 5%, cubes, EXP tickets, and more.
To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Artwork
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M https://maplestorym.nexon.com/
MapleStory M , launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and recently celebrated its 3-year anniversary with 16 million global downloads.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006140/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom